Astel­las dumps a PhI­II lung can­cer drug; GSK gets one suc­cess, one fail­ure in a pair of piv­otal Crohn’s tri­als

→ Japan’s Astel­las Phar­ma is punt­ing its Phase III drug ASP8273, halt­ing the late-stage SO­LAR tri­al eval­u­at­ing the ef­fi­ca­cy and safe­ty of ASP8273 ver­sus er­lotinib/gefi­tinib for the 1st line treat­ment metasta­t­ic or ad­vanced un­re­sectable non-small cell lung can­cer har­bor­ing sen­si­tiz­ing epi­der­mal growth fac­tor re­cep­tor (EGFR) mu­ta­tion. Astel­las says that the de­ci­sion to scrap the pro­gram was made on the rec­om­men­da­tion of the in­de­pen­dent mon­i­tor­ing board, but didn’t ex­plain what went wrong.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.